Matias-Morales FA
Mexico
Research Article
Association between Sclerostin and Bone Mineral Density in a Mexican Sample of Women with Rheumatoid Arthritis: A Pilot Study
Author(s): Vargas-Muñoz VM, Jimenez-Andrade MC, Villarreal-Salcido JC, Martinez-Martinez A, Acosta-Gonzalez RI, Lugo-Zamudio GE, Conde-Mercado JM, Barbosa-Cobos RE, Matias-Morales FA, Ramirez-Rosas MB and Jimenez-Andrade JMVargas-Muñoz VM, Jimenez-Andrade MC, Villarreal-Salcido JC, Martinez-Martinez A, Acosta-Gonzalez RI, Lugo-Zamudio GE, Conde-Mercado JM, Barbosa-Cobos RE, Matias-Morales FA, Ramirez-Rosas MB and Jimenez-Andrade JM
Introduction/objectives: Rheumatoid arthritis (RA) is associated with decreased bone mass and increased risk of fractures. However, mechanisms underlying this association are not fully understood. Thus, we quantified serum levels of sclerostin, a glycoprotein that inhibits bone formation, and determined its association with bone mineral density (BMD) and disease progression in RA patients.
Method: Forty-eight women (aged 25-83 years) with RA and 15 healthy women (aged-matched) were recruited to determine the association between serum sclerostin and BMD at femoral and vertebral level (L1-L4), by DEXA, body mass index (BMI), disease duration, disease activity score (DAS 28), C-Reactive protein and rheumatoid factor. Spearman correlation analyses were performed to determine the association between sclerostin and BMD and the additional variables.. View More»
